Peter Coolidge, senior equity trader at investment firm Brean Murray, said investors were worried that bio-terrorism could hurt economic activity. 'There's a real lingering fear that as the anthrax issue widens it strikes not only at the physical well-being of people, but of the well-being of the economy,' he added.